Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-416 in congenital factor X deficiency (phase I/III, Japan)
jRCT2031240288Phase 3Active, not recruiting
- Sponsor
- KM Biologics
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of KD-416 in factor X deficiency (FXD) (3 arms), sponsored by KM Biologics. Primary endpoints: Phase I pharmacokinetics parameters, Phase I FX:C geometric mean profile and 3 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
KD-416
03
Conditions
factor X deficiency (FXD)
Beyond the preview
Go deeper on jRCT2031240288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240288.